Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The new products include the COAG Line automated, semi-automated and POC systems manufactured by Diagon Hungary
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Equity raise to finance growth and investments in the biological space
Subscribe To Our Newsletter & Stay Updated
